Senores Pharmaceuticals Limited has informed the Exchange regarding additional disclosures to the Notice of Extra-Ordinary General Meeting dated January 07, 2026.
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Senores Pharmaceuticals has submitted amendments to the explanatory statement of its EGM Notice dated January 7, 2026, regarding the proposed preferential issue of 11,70,000 convertible equity warrants on a private placement basis. The amendment revises the 'Objects of the Preferential Issue' section, clarifying that a portion of the funds raised will be used to invest in Apnar Pharma Private Limited (in which Senores has already acquired 75% equity) by way of a loan to fund Apnar's working capital requirements, in one or more tranches. The company is providing this additional disclosure under SEBI LODR and ICDR regulations. All other contents of the EGM Notice remain unchanged. The revised disclosure is available on the company's and stock exchanges' websites.
This is a procedural clarification to an already announced preferential warrant issue, not a new event. Shareholders should note that part of the capital raised will be deployed into subsidiary Apnar Pharma for working capital, which could support operational expansion but also signals inter-group fund movement.